Corvus Pharmaceuticals Inc Stock
Corvus Pharmaceuticals Inc gained 1.840% today.
Our community is currently high on Corvus Pharmaceuticals Inc with 4 Buy predictions and 1 Sell predictions.
With a target price of 5 € there is potential for a 246.74% increase which would mean more than doubling the current price of 1.44 € for Corvus Pharmaceuticals Inc.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Corvus Pharmaceuticals Inc | 1.840% | 5.045% | -18.807% | 43.030% | -6.842% | -37.895% | -61.966% |
Ardelyx Inc. | 28.120% | 7.123% | -7.526% | 58.693% | 9.273% | 3.541% | - |
Evolus Inc | 10.280% | - | - | - | - | - | - |
Salarius Pharmaceuticals Inc. | 11.650% | -5.069% | 5.641% | -71.389% | -25.766% | -98.474% | -99.994% |
Comments
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock.
Show more
Ratings data for CRVS provided by MarketBeat